Cellectar Biosciences, Inc.
Clinical trials sponsored by Cellectar Biosciences, Inc., explained in plain language.
-
New radiation drug targets brain tumors in kids
Disease control OngoingThis early-stage trial is testing a new drug called CLR 131, a form of targeted radiotherapy, in 50 children, adolescents, and young adults (ages 10 to 25) with high-grade glioma that has returned or not responded to treatment. The drug is given through an IV and aims to deliver …
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
New radioactive drug targets childhood cancers that Won't quit
Disease control OngoingThis early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC